Indeed Snapshot

Track Seres Therapeutics reviews on Indeed to uncover insights on employee sentiment

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Profile Url Name Website Industry Description Revenue Headquarters location CEO Rating: CEO (%) Rating: CEO Responses Count Rating: Overall Happiness: Compensation score Happiness: Support score Happiness: Purpose score Happiness: Flexibility score Happiness: Energy score Happiness: Work Happiness score Happiness: Trust score Happiness: Learning score Happiness: Belonging score Happiness: Inclusion score Happiness: Overall score Happiness: Appreciation score Happiness: Achievement score Happiness: Responses Count Review Count Ratings Responses Count Rating: Culture & Values Rating: Compensation & Benefits Rating: Job Security & Advancement Rating: Senior Management Rating: Worklife Balance Interview: Duration Responses count Interview Duration Interview: Difficulty Responses count Interview Difficulty Interview: Experience Responses count Interview Experience Work Culture: Stressful (0) to Relaxed (1) Ratio Work Culture: Slow Paced (0) to Fast Paced (1) Ratio Work Culture: Competitive (0) to Collaborative (1) Ratio Date Added Date Updated Company Name Sector Industry
nasdaq:mcrb https://www.indeed.com/cmp/seres-therapeutics,-inc. Aug 29th, 2022 12:00AM Open Seres Therapeutics, Inc. Pharmaceutical & Biotechnology Our mission is to transform the lives of patients worldwide with revolutionary microbiome-based therapeutics. Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize the treatment of a wide range of diseases by modulating the function of the human microbiome. Our team of drug development experts discover and design new medicines using our proprietary microbiome therapeutics platform. Founded: 2010 by Flagship VentureLabs® Headquarters: Cambridge, MA Our Name: Seres is the plural noun of the word Sere, defined as a series of ecological communities formed in ecological succession CEO: Eric Shaff Lead Program: SER-109 is designed to prevent further recurrences of recurrent Clostridium difficile infection (C. difficile) in patients with a history of multiple infections by modulating the disrupted microbiome to a state that resists C. difficile colonization and growth. SER-109 is an oral microbiome therapeutic candidate consisting of a consortium of highly purified Firmicutes spores, which normally live in the healthy microbiome. The SER-109 manufacturing purification process is designed to remove unwanted microbes thereby reducing the risk of pathogen transmission beyond donor screening alone. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. RRv1_UNDER_1M Cambridge, MA Eric Shaff 3.10 7.00 7.00 3.00 3.10 2.90 2.90 3.40 6.00 About a week 6.00 MEDIUM 6.00 AVERAGE Aug 29th, 2022 12:15PM Aug 29th, 2022 12:15PM Seres Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:mcrb https://www.indeed.com/cmp/seres-therapeutics,-inc. Aug 28th, 2022 12:00AM Open Seres Therapeutics, Inc. Pharmaceutical & Biotechnology Our mission is to transform the lives of patients worldwide with revolutionary microbiome-based therapeutics. Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize the treatment of a wide range of diseases by modulating the function of the human microbiome. Our team of drug development experts discover and design new medicines using our proprietary microbiome therapeutics platform. Founded: 2010 by Flagship VentureLabs® Headquarters: Cambridge, MA Our Name: Seres is the plural noun of the word Sere, defined as a series of ecological communities formed in ecological succession CEO: Eric Shaff Lead Program: SER-109 is designed to prevent further recurrences of recurrent Clostridium difficile infection (C. difficile) in patients with a history of multiple infections by modulating the disrupted microbiome to a state that resists C. difficile colonization and growth. SER-109 is an oral microbiome therapeutic candidate consisting of a consortium of highly purified Firmicutes spores, which normally live in the healthy microbiome. The SER-109 manufacturing purification process is designed to remove unwanted microbes thereby reducing the risk of pathogen transmission beyond donor screening alone. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. RRv1_UNDER_1M Cambridge, MA Eric Shaff 3.10 7.00 7.00 3.00 3.10 2.90 2.90 3.40 6.00 About a week 6.00 MEDIUM 6.00 AVERAGE Aug 28th, 2022 05:14AM Aug 28th, 2022 05:14AM Seres Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:mcrb https://www.indeed.com/cmp/seres-therapeutics,-inc. Aug 27th, 2022 12:00AM Open Seres Therapeutics, Inc. Pharmaceutical & Biotechnology Our mission is to transform the lives of patients worldwide with revolutionary microbiome-based therapeutics. Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize the treatment of a wide range of diseases by modulating the function of the human microbiome. Our team of drug development experts discover and design new medicines using our proprietary microbiome therapeutics platform. Founded: 2010 by Flagship VentureLabs® Headquarters: Cambridge, MA Our Name: Seres is the plural noun of the word Sere, defined as a series of ecological communities formed in ecological succession CEO: Eric Shaff Lead Program: SER-109 is designed to prevent further recurrences of recurrent Clostridium difficile infection (C. difficile) in patients with a history of multiple infections by modulating the disrupted microbiome to a state that resists C. difficile colonization and growth. SER-109 is an oral microbiome therapeutic candidate consisting of a consortium of highly purified Firmicutes spores, which normally live in the healthy microbiome. The SER-109 manufacturing purification process is designed to remove unwanted microbes thereby reducing the risk of pathogen transmission beyond donor screening alone. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. RRv1_UNDER_1M Cambridge, MA Eric Shaff 3.10 7.00 7.00 3.00 3.10 2.90 2.90 3.40 6.00 About a week 6.00 MEDIUM 6.00 AVERAGE Aug 27th, 2022 04:34AM Aug 27th, 2022 04:34AM Seres Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:mcrb https://www.indeed.com/cmp/seres-therapeutics,-inc. Aug 25th, 2022 12:00AM Open Seres Therapeutics, Inc. Pharmaceutical & Biotechnology Our mission is to transform the lives of patients worldwide with revolutionary microbiome-based therapeutics. Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize the treatment of a wide range of diseases by modulating the function of the human microbiome. Our team of drug development experts discover and design new medicines using our proprietary microbiome therapeutics platform. Founded: 2010 by Flagship VentureLabs® Headquarters: Cambridge, MA Our Name: Seres is the plural noun of the word Sere, defined as a series of ecological communities formed in ecological succession CEO: Eric Shaff Lead Program: SER-109 is designed to prevent further recurrences of recurrent Clostridium difficile infection (C. difficile) in patients with a history of multiple infections by modulating the disrupted microbiome to a state that resists C. difficile colonization and growth. SER-109 is an oral microbiome therapeutic candidate consisting of a consortium of highly purified Firmicutes spores, which normally live in the healthy microbiome. The SER-109 manufacturing purification process is designed to remove unwanted microbes thereby reducing the risk of pathogen transmission beyond donor screening alone. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. RRv1_UNDER_1M Cambridge, MA Eric Shaff 3.10 7.00 7.00 3.00 3.10 2.90 2.90 3.40 6.00 About a week 6.00 MEDIUM 6.00 AVERAGE Aug 25th, 2022 09:13AM Aug 25th, 2022 09:13AM Seres Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:mcrb https://www.indeed.com/cmp/seres-therapeutics,-inc. Aug 23rd, 2022 12:00AM Open Seres Therapeutics, Inc. Biotechnology Our mission is to transform the lives of patients worldwide with revolutionary microbiome-based therapeutics. Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize the treatment of a wide range of diseases by modulating the function of the human microbiome. Our team of drug development experts discover and design new medicines using our proprietary microbiome therapeutics platform. Founded: 2010 by Flagship VentureLabs® Headquarters: Cambridge, MA Our Name: Seres is the plural noun of the word Sere, defined as a series of ecological communities formed in ecological succession CEO: Eric Shaff Lead Program: SER-109 is designed to prevent further recurrences of recurrent Clostridium difficile infection (C. difficile) in patients with a history of multiple infections by modulating the disrupted microbiome to a state that resists C. difficile colonization and growth. SER-109 is an oral microbiome therapeutic candidate consisting of a consortium of highly purified Firmicutes spores, which normally live in the healthy microbiome. The SER-109 manufacturing purification process is designed to remove unwanted microbes thereby reducing the risk of pathogen transmission beyond donor screening alone. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. RRv1_UNDER_1M 200 Sidney St, Cambridge, MA 02139 Eric Shaff 3.10 7.00 7.00 3.00 3.10 2.90 2.90 3.40 6.00 About a week 6.00 MEDIUM 6.00 AVERAGE Aug 23rd, 2022 11:06AM Aug 23rd, 2022 11:06AM Seres Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:mcrb https://www.indeed.com/cmp/seres-therapeutics,-inc. Aug 21st, 2022 12:00AM Open Seres Therapeutics, Inc. Biotechnology Our mission is to transform the lives of patients worldwide with revolutionary microbiome-based therapeutics. Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize the treatment of a wide range of diseases by modulating the function of the human microbiome. Our team of drug development experts discover and design new medicines using our proprietary microbiome therapeutics platform. Founded: 2010 by Flagship VentureLabs® Headquarters: Cambridge, MA Our Name: Seres is the plural noun of the word Sere, defined as a series of ecological communities formed in ecological succession CEO: Eric Shaff Lead Program: SER-109 is designed to prevent further recurrences of recurrent Clostridium difficile infection (C. difficile) in patients with a history of multiple infections by modulating the disrupted microbiome to a state that resists C. difficile colonization and growth. SER-109 is an oral microbiome therapeutic candidate consisting of a consortium of highly purified Firmicutes spores, which normally live in the healthy microbiome. The SER-109 manufacturing purification process is designed to remove unwanted microbes thereby reducing the risk of pathogen transmission beyond donor screening alone. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. RRv1_UNDER_1M 200 Sidney St, Cambridge, MA 02139 Eric Shaff 3.10 7.00 7.00 3.00 3.10 2.90 2.90 3.40 6.00 About a week 6.00 MEDIUM 6.00 AVERAGE Aug 21st, 2022 12:50PM Aug 21st, 2022 12:50PM Seres Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:mcrb https://www.indeed.com/cmp/seres-therapeutics,-inc. Aug 20th, 2022 12:00AM Open Seres Therapeutics, Inc. Biotechnology Our mission is to transform the lives of patients worldwide with revolutionary microbiome-based therapeutics. Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize the treatment of a wide range of diseases by modulating the function of the human microbiome. Our team of drug development experts discover and design new medicines using our proprietary microbiome therapeutics platform. Founded: 2010 by Flagship VentureLabs® Headquarters: Cambridge, MA Our Name: Seres is the plural noun of the word Sere, defined as a series of ecological communities formed in ecological succession CEO: Eric Shaff Lead Program: SER-109 is designed to prevent further recurrences of recurrent Clostridium difficile infection (C. difficile) in patients with a history of multiple infections by modulating the disrupted microbiome to a state that resists C. difficile colonization and growth. SER-109 is an oral microbiome therapeutic candidate consisting of a consortium of highly purified Firmicutes spores, which normally live in the healthy microbiome. The SER-109 manufacturing purification process is designed to remove unwanted microbes thereby reducing the risk of pathogen transmission beyond donor screening alone. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. RRv1_UNDER_1M 200 Sidney St, Cambridge, MA 02139 Eric Shaff 3.10 7.00 7.00 3.00 3.10 2.90 2.90 3.40 6.00 About a week 6.00 MEDIUM 6.00 AVERAGE Aug 20th, 2022 02:27PM Aug 20th, 2022 02:27PM Seres Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:mcrb https://www.indeed.com/cmp/seres-therapeutics,-inc. Aug 19th, 2022 12:00AM Open Seres Therapeutics, Inc. Biotechnology Our mission is to transform the lives of patients worldwide with revolutionary microbiome-based therapeutics. Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize the treatment of a wide range of diseases by modulating the function of the human microbiome. Our team of drug development experts discover and design new medicines using our proprietary microbiome therapeutics platform. Founded: 2010 by Flagship VentureLabs® Headquarters: Cambridge, MA Our Name: Seres is the plural noun of the word Sere, defined as a series of ecological communities formed in ecological succession CEO: Eric Shaff Lead Program: SER-109 is designed to prevent further recurrences of recurrent Clostridium difficile infection (C. difficile) in patients with a history of multiple infections by modulating the disrupted microbiome to a state that resists C. difficile colonization and growth. SER-109 is an oral microbiome therapeutic candidate consisting of a consortium of highly purified Firmicutes spores, which normally live in the healthy microbiome. The SER-109 manufacturing purification process is designed to remove unwanted microbes thereby reducing the risk of pathogen transmission beyond donor screening alone. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. RRv1_UNDER_1M 200 Sidney St, Cambridge, MA 02139 Eric Shaff 3.10 7.00 7.00 3.00 3.10 2.90 2.90 3.40 6.00 About a week 6.00 MEDIUM 6.00 AVERAGE Aug 19th, 2022 12:50PM Aug 19th, 2022 12:50PM Seres Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:mcrb https://www.indeed.com/cmp/seres-therapeutics,-inc. Aug 18th, 2022 12:00AM Open Seres Therapeutics, Inc. Biotechnology Our mission is to transform the lives of patients worldwide with revolutionary microbiome-based therapeutics. Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize the treatment of a wide range of diseases by modulating the function of the human microbiome. Our team of drug development experts discover and design new medicines using our proprietary microbiome therapeutics platform. Founded: 2010 by Flagship VentureLabs® Headquarters: Cambridge, MA Our Name: Seres is the plural noun of the word Sere, defined as a series of ecological communities formed in ecological succession CEO: Eric Shaff Lead Program: SER-109 is designed to prevent further recurrences of recurrent Clostridium difficile infection (C. difficile) in patients with a history of multiple infections by modulating the disrupted microbiome to a state that resists C. difficile colonization and growth. SER-109 is an oral microbiome therapeutic candidate consisting of a consortium of highly purified Firmicutes spores, which normally live in the healthy microbiome. The SER-109 manufacturing purification process is designed to remove unwanted microbes thereby reducing the risk of pathogen transmission beyond donor screening alone. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. RRv1_UNDER_1M 200 Sidney St, Cambridge, MA 02139 Eric Shaff 3.10 7.00 7.00 3.00 3.10 2.90 2.90 3.40 6.00 About a week 6.00 MEDIUM 6.00 AVERAGE Aug 18th, 2022 04:34AM Aug 18th, 2022 04:34AM Seres Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:mcrb https://www.indeed.com/cmp/seres-therapeutics,-inc. Aug 17th, 2022 12:00AM Open Seres Therapeutics, Inc. Biotechnology Our mission is to transform the lives of patients worldwide with revolutionary microbiome-based therapeutics. Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize the treatment of a wide range of diseases by modulating the function of the human microbiome. Our team of drug development experts discover and design new medicines using our proprietary microbiome therapeutics platform. Founded: 2010 by Flagship VentureLabs® Headquarters: Cambridge, MA Our Name: Seres is the plural noun of the word Sere, defined as a series of ecological communities formed in ecological succession CEO: Eric Shaff Lead Program: SER-109 is designed to prevent further recurrences of recurrent Clostridium difficile infection (C. difficile) in patients with a history of multiple infections by modulating the disrupted microbiome to a state that resists C. difficile colonization and growth. SER-109 is an oral microbiome therapeutic candidate consisting of a consortium of highly purified Firmicutes spores, which normally live in the healthy microbiome. The SER-109 manufacturing purification process is designed to remove unwanted microbes thereby reducing the risk of pathogen transmission beyond donor screening alone. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. RRv1_UNDER_1M 200 Sidney St, Cambridge, MA 02139 Eric Shaff 3.10 7.00 7.00 3.00 3.10 2.90 2.90 3.40 6.00 About a week 6.00 MEDIUM 6.00 AVERAGE Aug 17th, 2022 10:13AM Aug 17th, 2022 10:13AM Seres Therapeutics Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.